Project Grant HT94252310681
Award Date
8/1/23
Completion Date
7/31/26
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Hershey, PA 17033, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, provides $2,985,093.00 to Plus Therapeutics, Inc. (Cytori) to develop a novel targeted radiotherapeutic for the treatment of pediatric high-grade glioma (HGG) and ependymoma. The award period runs from September 1, 2024 to August 31, 2027. The Military Medical Research and Development program supports advanced biomedical research aimed at transforming...
The Defense Health Agency awarded a $1,528,727.00 Project Grant to Children's Research Institute, a subsidiary of Children's National Medical Center, to develop SGT-53, a novel nanomedicine that crosses the blood-brain barrier and augments immunotherapeutic response in pediatric brain cancers. This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for Service Members and the...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
The Department of the Army Medical Command awarded a $884,997 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program. The three-year grant will fund research to intervene in the TP53 pathway phosphatome in pediatric high-grade gliomas. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research that investigates medical solutions...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $544,892 to the University of Texas Health Science Center at Houston to develop a novel peptide-drug conjugate for precision-targeted DNA damage in neuroendocrine tumors. The award commenced on August 1, 2025 and is set to conclude on July 31, 2028. The goal of this research is to transform healthcare for military service members, veterans, and the broader...
This $626,000 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports Emory University's research on developing immune-competent 3D bioprinted organoids to study and target barriers to cellular therapy for neuroblastoma. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical solutions. The 2-year award period runs from July 15, 2025 to July...
The Defense Health Agency awarded a $1,535,920.00 Project Grant to the Translational Genomics Research Institute (TGen) under the Military Medical Research and Development program (CFDA 12.420). The grant supports TGen's research on genomic structural mutations associated with telomere dysfunction in glioblastoma cells and patients. The 4-year project will utilize advanced genomic analysis and sequencing techniques to gain insights into the molecular mechanisms driving glioblastoma, a highly...
The federal Project Grant award of $161,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Duke University to investigate breast cancer brain metastases. The research aims to integrate immunogenomic and phenotypic vulnerabilities to improve outcomes for this challenging condition. The award period runs from April 1, 2025 to March 31, 2026. This grant is part of the Defense Health Agency's strategic...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...